Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
Analysts anticipate Twist Bioscience to report an earnings per share (EPS) of $-0.46. Anticipation surrounds Twist Bioscience ...
Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 ...
TipRanks on MSN
FDA appoints Richard Pazdur as Director of CDER
The U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced that Richard Pazdur, M.D., has been appointed ...
Stifel 2025 Healthcare Conference November 11, 2025 10:00 AM ESTCompany ParticipantsOlivier Loeillot - President, CEO ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
As Catalent sets up shop in a new headquarters and refines its corporate image under the ownership of Novo Holdings, the CDMO ...
UniQure stock dropped after the FDA sent feedback on the company's pending treatment for Huntington's disease. Read more on ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...
A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback